Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Issam Zineh

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Clinical Pharmacology and Therapeutics|December 14, 2004
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertensionIssam Zineh, Amber L Beitelshees, Andrea Gaedigk, et al.
Clinical Pharmacology and Therapeutics|October 8, 2017
Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation StudyJose Vicente, Robbert Zusterzeel, Lars Johannesen, et al.
The American Journal of Cardiology|January 16, 2007
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failureJaekyu Shin, Maximilian T Lobmeyer, Yan Gong, et al.
Clinical Pharmacology and Therapeutics|January 7, 2021
Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee MeetingMartina D Sahre, Lauren Milligan, Rajanikanth Madabushi, et al.
Pharmacogenetics and Genomics|February 11, 2010
Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromesAmber L Beitelshees, Brian N Finck, Teresa C Leone, et al.
Journal of the American Heart Association|November 7, 2012
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working groupKiran Musunuru, Dan M Roden, Robin Boineau, et al.
American Heart Journal|March 3, 2009
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studyJulie A Johnson, Eric Boerwinkle, Issam Zineh, et al.
Hypertension (Dallas, Tex. : 1979)|November 18, 2009
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medicationsRhonda M Cooper-DeHoff, Sheron Wen, Amber L Beitelshees, et al.
Clinical Pharmacology and Therapeutics|February 13, 2024
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID-19 Under the Emergency Use AuthorizationQi Liu, Raj Nair, Ruihao Huang, et al.
Journal of Translational Medicine|March 12, 2008
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome EvaluationMichael A Pacanowski, Issam Zineh, Haihong Li, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Clinical Pharmacology and Therapeutics|December 14, 2004
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertensionIssam Zineh, Amber L Beitelshees, Andrea Gaedigk, et al.
Clinical Pharmacology and Therapeutics|October 8, 2017
Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation StudyJose Vicente, Robbert Zusterzeel, Lars Johannesen, et al.
The American Journal of Cardiology|January 16, 2007
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failureJaekyu Shin, Maximilian T Lobmeyer, Yan Gong, et al.
Clinical Pharmacology and Therapeutics|January 7, 2021
Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee MeetingMartina D Sahre, Lauren Milligan, Rajanikanth Madabushi, et al.
Pharmacogenetics and Genomics|February 11, 2010
Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromesAmber L Beitelshees, Brian N Finck, Teresa C Leone, et al.
Journal of the American Heart Association|November 7, 2012
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working groupKiran Musunuru, Dan M Roden, Robin Boineau, et al.
American Heart Journal|March 3, 2009
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studyJulie A Johnson, Eric Boerwinkle, Issam Zineh, et al.
Hypertension (Dallas, Tex. : 1979)|November 18, 2009
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medicationsRhonda M Cooper-DeHoff, Sheron Wen, Amber L Beitelshees, et al.
Clinical Pharmacology and Therapeutics|February 13, 2024
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID-19 Under the Emergency Use AuthorizationQi Liu, Raj Nair, Ruihao Huang, et al.
Journal of Translational Medicine|March 12, 2008
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome EvaluationMichael A Pacanowski, Issam Zineh, Haihong Li, et al.
Pageof 13